Moreover, various Rho regulator inhibitors including high selective Cdc42 inhibitor ML141 [194], Scaff10-8 inhibitor of A-kinase anchoring protein (AKAP-Lbc)-mediated RhoA activation [195], inhibitor of Lbc-RhoA interaction [196], C21 chemical inhibitor of DOCK5 [197], and ITX3 inhibitor of the Trio/RhoG/Rac1 pathway [198], revealed their potential in cancer therapy; however, there is no their evidence regarding ovarian, cervical, and endometrial cancer. Here, CDC42 is linked to cancer.